Search results

1. The impact of H3 histamine receptor modulation on oligodendrogenesis and neurogenesis: a new strategy for the treatment …

Principal investigator: Maciej Degutis

Instytut Farmakologii PAN

Call: PRELUDIUM 24, Panel: NZ5

2. Design and Pharmacological Evaluation of Marine Alkaloid-Inspired 5-HT2A Receptor Ligands

Principal investigator: Szymon Kazimierz Kordylewski

Instytut Farmakologii PAN

Call: PRELUDIUM 24, Panel: NZ1

3. NMR Spectroscopy as Molecular Language: A Deep Learning Approach to Bioactivity Prediction

Principal investigator: Arkadiusz Bogumił Leniak

Instytut Farmakologii PAN

Call: PRELUDIUM 24, Panel: NZ7

4. Positioning the aryl hydrocarbon receptor (AhR) as a new target for pharmacotherapy of sporadic Alzheimer disease: verif…

Principal investigator: prof. Małgorzata Kajta

Instytut Farmakologii PAN

Call: OPUS 28, Panel: NZ7

5. A new concept of inhibiting the progression of Alzheimer's disease based on the modification of the blood-brain barrier …

Principal investigator: prof. Agnieszka Basta-Kaim

Instytut Farmakologii PAN

Call: OPUS 28, Panel: NZ4

6. Decoding the novel role of the histamine H3 receptor in opioid-induced analgesia and hyperalgesia: studies toward innova…

Principal investigator: dr Katarzyna Popiołek-Barczyk

Instytut Farmakologii PAN

Call: OPUS 28, Panel: NZ7

7. Reinforcement sensitivity phenotypes as determinants of various motivational styles of alcohol drinking: craving for rew…

Principal investigator: prof. Rafał Ryguła

Instytut Farmakologii PAN

Call: OPUS 28, Panel: HS6

8. Modulation of 5-HT7 receptor signaling as common mechanism involved in the long-lasting antidepressant effects of typica…

Principal investigator: dr Barbara Wanda Chruścicka-Smaga

Instytut Farmakologii PAN

Call: SONATA 20, Panel: NZ7

9. "Integrated Fixed-Dose Combination Drugs in Depression Therapy: A New Standard of Treatment and Mechanism of Action Stud…

Principal investigator: prof. Gabriel Piotr Nowak

Instytut Farmakologii PAN

Call: OPUS 28, Panel: NZ7

10. Effects of ketamine optical isomers on motivation and decision-making in rats using deep learning for behavioral analysi…

Principal investigator: dr Natalia Alicja Malikowska-Racia

Instytut Farmakologii PAN

Call: SONATA 20, Panel: NZ7

11. Mechanisms of Antidepressant Action of Psilocybin: The Role of 5-HT2B-5-HT1A Receptor Dimerization and GSK-3β Activation…

Principal investigator: dr hab. Agata Faron-Górecka

Instytut Farmakologii PAN

Call: OPUS 27, Panel: NZ7

12. Modeling Progression of α-Synucleinopathy in Noradrenergic and Serotonergic Systems – Possible Link with Prodromal Sympt…

Principal investigator: Anna Hajam Alwani

Instytut Farmakologii PAN

Call: PRELUDIUM 23, Panel: NZ4

13. Potential pharmacological strategies aimed at alleviating cognitive dysfunctions accompanying oncological therapy while …

Principal investigator: dr hab. Joanna Monika Wierońska

Instytut Farmakologii PAN

Call: OPUS 26, Panel: NZ5

14. Semaglutide and neurodevelopment: investigating risks arising from prenatal exposure to a widely popular drug for diabet…

Principal investigator: dr hab. Agnieszka Wnuk

Instytut Farmakologii PAN

Call: OPUS 26, Panel: NZ7

15. Optogenetic and chemogenetic identification of brain circuits and cellular mechanisms underlying antidepressants resista…

Principal investigator: prof. Mariusz Papp

Instytut Farmakologii PAN

Call: OPUS 26, Panel: NZ7

16. ROS-Scavenging Magnetic Nanozymes with Remote Activation for Alzheimer Disease

Principal investigator: dr hab. Anna Ludwika Haduch

Instytut Farmakologii PAN

Call: M-ERA.NET 3 Call 2023, Panel: NZ5

17. The effect of prolonged treatment with the new antipsychotics brexpiprazole and lumateperone on human liver function usi…

Principal investigator: dr Przemysław Jan Danek

Instytut Farmakologii PAN

Call: OPUS 26, Panel: NZ4

18. Impact of maternal monosaccharide diet on dams and offspring hippocampus development.

Principal investigator: Kacper Karol Witek

Instytut Farmakologii PAN

Call: PRELUDIUM 22, Panel: NZ1

19. The cross-talk between 5-HTR2A and mGluR2 as a window for antidepressant effects of psilocybin.

Principal investigator: prof. Andrzej Mikołaj Pilc

Instytut Farmakologii PAN

Call: OPUS 25, Panel: NZ7

20. Plasticity of neuroanatomically identified synaptic inputs and functions of the dorsal raphe nucleus in an animal model …

Principal investigator: prof. Krzysztof Tokarski

Instytut Farmakologii PAN

Call: OPUS 25, Panel: NZ4

21. "I like to move it, move it" – molecular dynamics-driven optimization of ligand residence time as an opportunity to impr…

Principal investigator: dr hab. Sabina Marta Podlewska

Instytut Farmakologii PAN

Call: OPUS 25, Panel: NZ7

22. Selective PPARγ modulation by amorfrutin B as a novel therapeutic approach to chemotherapy-induced damage to mammalian b…

Principal investigator: Bernadeta Angelika Pietrzak-Wawrzyńska

Instytut Farmakologii PAN

Call: PRELUDIUM 22, Panel: NZ7

23. Early-life programming for neurodevelopmental disorders: search for a prodrome target within the vascular network in a r…

Principal investigator: prof. Małgorzata Maria Filip

Instytut Farmakologii PAN

Call: OPUS 23, Panel: NZ4

24. Brain cytochrome P450 as a new target for the treatment of neurological and psychiatric diseases. Studies with human neu…

Principal investigator: prof. Władysława Anna Daniel

Instytut Farmakologii PAN

Call: OPUS 23, Panel: NZ7

25. The developmental changes in the endogenous opioid system associated with altered sensitivity to reward during adolescen…

Principal investigator: Klaudia Weronika Misiołek

Instytut Farmakologii PAN

Call: PRELUDIUM 21, Panel: NZ4

26. The role of simultaneous and individual modulation of μ-opioid, sigma-1 and histamine H3 receptors as a new therapeutic …

Principal investigator: dr Katarzyna Anna Szczepańska

Instytut Farmakologii PAN

Call: OPUS 23, Panel: NZ7

27. Selective modulation of PPARγ signaling as a new therapeutic strategy for Alzheimer's disease

Principal investigator: Karolina Barbara Przepiórska-Drońska

Instytut Farmakologii PAN

Call: PRELUDIUM 21, Panel: NZ7

28. The evaluation of therapeutic potential of β-caryophyllene in animal schizophrenia model - behavioral and molecular stud…

Principal investigator: dr Magdalena Białoń

Instytut Farmakologii PAN

Call: PRELUDIUM 21, Panel: NZ7

29. Genetics of GR-dependent behavioral traits in humans

Principal investigator: dr hab. Michał Korostyński

Instytut Farmakologii PAN

Call: OPUS 23, Panel: NZ5

30. Enhancement of antidepressant therapy by combined administration of hyperforin and ketamine: behavioral and molecular st…

Principal investigator: dr Bartłomiej Pochwat

Instytut Farmakologii PAN

Call: SONATA 17, Panel: NZ7

31. Cognitive impairment in chronic pain - CBD as the undervalued remedy.

Principal investigator: prof. Katarzyna Maria Starowicz-Bubak

Instytut Farmakologii PAN

Call: OPUS 22, Panel: NZ7

32. Biological roles of transcriptional networks activated in the brain by psychotropic drugs

Principal investigator: dr hab. Michał Korostyński

Instytut Farmakologii PAN

Call: PRELUDIUM BIS 3, Panel: NZ7

33. Translational and interdisciplinary investigation of phenotypes of reinforcement sensitivity as predictors of the respon…

Principal investigator: dr hab. Rafał Ryguła

Instytut Farmakologii PAN

Call: OPUS 22, Panel: HS6

34. Brain GABAB receptors as determinants of obesity phenotypes: evaluation of adolescent female and male rats

Principal investigator: prof. Małgorzata Maria Filip

Instytut Farmakologii PAN

Call: OPUS 22, Panel: NZ5

35. New approach to the treatment of Alzheimer's disease targetingresolution of inflammation and modulation of biomechanical…

Principal investigator: prof. Agnieszka Basta-Kaim

Instytut Farmakologii PAN

Call: OPUS 22, Panel: NZ4

36. The role of the immune checkpoints in the pathomechanism of depressive disorders.

Principal investigator: prof. Marta Wanda Kubera

Instytut Farmakologii PAN

Call: OPUS 22, Panel: NZ6

37. New strategies in the pharmacotherapy of neuropathic pain based on modulation of the chemokine system and its influence …

Principal investigator: prof. Joanna Gabriela Mika

Instytut Farmakologii PAN

Call: OPUS 22, Panel: NZ7

38. New post-treatment strategy against stroke and perinatal asphyxia – a novel approach based on a selective activation of …

Principal investigator: dr hab. Agnieszka Wnuk

Instytut Farmakologii PAN

Call: SONATA 17, Panel: NZ7

39. Maternal obesity as a risk factor of autism spectrum disorder in offspring - in search of the role of the gut microbiota…

Principal investigator: dr Dawid Mateusz Gawliński

Instytut Farmakologii PAN

Call: OPUS 22, Panel: NZ5

40. Chronic pain in obesity: from cellular mechanisms to new strategies for targeted therapy.

Principal investigator: dr Anna Piotrowska-Murzyn

Instytut Farmakologii PAN

Call: SONATA 17, Panel: NZ5

41. A premotor disease signature for ALS

Principal investigator: dr Wojciech Kuban

Instytut Farmakologii PAN

Call: JPco-fuND2 Call 2021, Panel: NZ7

42. Novel hope for diseased joints: a polymer-based treatment to promoteregenerative strategies for patients with osteoarthr…

Principal investigator: Marta Kędziora

Instytut Farmakologii PAN

Call: PRELUDIUM 20, Panel: NZ7

43. Investigating the role of the focal adhesion kinase and its related signaling pathways in glucocorticoid- and stress-ind…

Principal investigator: Michał Józef Wilczkowski

Instytut Farmakologii PAN

Call: PRELUDIUM 20, Panel: NZ4

44. Impact of pharmacogenetic profiles on depression treatment outcomes

Principal investigator: dr Małgorzata Maria Borczyk

Instytut Farmakologii PAN

Call: SONATINA 5, Panel: NZ2

45. Selective activation of non-nuclear Estrogen Receptor signaling with PaPE-1 as a novel therapeutic approach for sporadic…

Principal investigator: prof. Małgorzata Kajta

Instytut Farmakologii PAN

Call: OPUS 20, Panel: NZ7

46. The effect of omega-3 fatty acid-enriched diet on the myelination impairment and the depression-like phenotype induced b…

Principal investigator: dr Irena Maria Smaga-Maślanka

Instytut Farmakologii PAN

Call: SONATA 16, Panel: NZ5

47. Prenatal exposure to glucocorticoids as a risk factor for depression - the importance of epigenetic mechanisms in the br…

Principal investigator: dr Katarzyna Elżbieta Głombik

Instytut Farmakologii PAN

Call: SONATA 16, Panel: NZ7

48. Molecular profiling of novel antipsychotic drug candidates

Principal investigator: dr hab. Jan Manuel Rodriguez Parkitna

Instytut Farmakologii PAN

Call: OPUS 20, Panel: NZ7

49. Spatial analysis of the effects of L-DOPA on gene expression in the prefrontal cortex in a mouse model of Parkinson's di…

Principal investigator: dr Anna Aleksandra Radlicka-Borysewska

Instytut Farmakologii PAN

Call: PRELUDIUM 19, Panel: NZ4

50. Neurochemical basis of antidepressive properties of psychedelics in rodent model of depression

Principal investigator: prof. Krystyna Czesława Gołembiowska

Instytut Farmakologii PAN

Call: OPUS 19, Panel: NZ7

Projects search